Supplement marketing firm Basic Research is preparing an aggressive international marketing campaign for the ephedra alternative Zantrex-3.
The company claims that the product produces around 546 per cent more weight-loss than the best-selling ephedra product Xenadrine(R) RFA-1.
"We expect sales to continue in North America and rapidly expand into Europe and Asia," said CEO Dennis Gay. "We've received inquiries from just about every country in the EU and have already sold thousands of units into Hong Kong, Singapore, Mexico and Canada. Apparently America was not the only country looking for a replacement for ephedra."
The company is clearly aiming to capitalise on recent fears over the ephedra herb, used widely until now in weight-loss and stimulant supplements. Other manufacturers of dietary supplements have also launched alternatives to the popular herbal compound in recent months.
The high-energy diet pill, made by Zoller Laboratories in Salt Lake City, Utah, has already broken GNC sales records, according to the supplement company, with nationwide sales exceeding 300,000 bottles in less than 30 days of retail availability.
Gay claims that Zantrex-3 has solid substantiation to support its weight-loss claims. "In a comparison of published clinical trials, Zantrex-3's active weight-loss compound was shown to deliver more than five times the weight loss of Xenadrine RFA-1. However, our retailers tell us it's the energy component that's been bringing people back to their stores for more."
The product contains a complex of xanthines [caffeine and caffeine-like substances] with a patented compound that helps speed absorption, and provides the energy boost.